REGENERON PHARMACEUTICALS, INC. (REGN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
REGN currently has 1.82M outstanding shares. with minimal authorized share overhang for future dilution. The company has not diluted shareholders through share issuances in the past 2 years, which is positive for existing holders.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 29, 2026 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Oct 28, 2025 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Aug 01, 2025 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Apr 29, 2025 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Feb 05, 2025 |
10-K filing | 1.8M shares outstanding |
1.8M | 0 |
| Oct 31, 2024 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Aug 01, 2024 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| May 02, 2024 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Feb 05, 2024 |
10-K filing | 1.8M shares outstanding |
1.8M | 0 |
| Nov 02, 2023 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Aug 03, 2023 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| May 04, 2023 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Feb 06, 2023 |
10-K filing | 1.8M shares outstanding |
1.8M | 0 |
| Nov 03, 2022 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Aug 03, 2022 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| May 04, 2022 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Feb 07, 2022 |
10-K filing | 1.8M shares outstanding |
1.8M | 0 |
| Nov 04, 2021 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Sep 16, 2021 |
8-K filing: Regeneron entered into an agreement with the U.S. Government to supply an additional 1.4 million doses of REGEN-COVTM for $2.940 billion. ($2940.0M proceeds) |
1.8M | 0 |
| Aug 05, 2021 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| May 06, 2021 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Feb 08, 2021 |
10-K filing | 1.8M shares outstanding |
1.8M | 0 |
| Nov 05, 2020 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Aug 05, 2020 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| May 29, 2020 |
8-K filing: Regeneron entered into an underwriting agreement with Sanofi and underwriters for a secondary offering of common stock, a stock repurchase agreement with Sanofi to repurchase shares, an amendment to the investor agreement, and a bridge loan facility agreement. ($5000.0M proceeds) |
1.8M | 0 |
| May 05, 2020 |
10-Q filing | 1.8M shares outstanding |
1.8M | 0 |
| Feb 07, 2020 |
10-K filing | 1.9M shares outstanding |
1.9M | 0 |